MSN 611 MIDTERM PHARMACOLOGY EXAM
QUESTIONS WITH CORRECT ANSWERS
Histamine |that |is |not |found |within |mast |cells |functions | CORRECT |ANSWER>>>as |a
|neurotransmitter |in |the |brain |and |is |involved |with |neuroendocrine |control, |cardiovascular |functions,
|thermal |and |weight |regulation, |and |sleep |and |arousal |balance
what |cells |release |histamine |in |the |stomach? | CORRECT |ANSWER>>>enterochromaffin-like
|(ECL) |cells
Toxicity |of |antihistamines |has |been |reported |in |incidents |of |interactions |with: | CORRECT
|ANSWER>>>liver |enzymes
Toxic |effect |of |first-generation |antihistamines | CORRECT |ANSWER>>>convulsions, |postural
|hypotension, |and |cardiac |arrhythmias
Know |anaphylaxis | CORRECT |ANSWER>>>
Central |nervous |system |side |effect |of |antihistamines |in |the |elderly | CORRECT
|ANSWER>>>BEERs |list,
Indication |H2 |antihistamines | CORRECT |ANSWER>>>used |to |inhibit |secretion |of |gastric |cid
|with |GI |disorders
Know |initial |selection |of |antimicrobial |therapy | CORRECT |ANSWER>>>
Mechanism |of |food-drug |or |drug-drug |interactions |with |antibacterial |medications | CORRECT
ANSWER>>>
Know |multiple |drug |combination |treatment |for |tuberculosis | CORRECT |ANSWER>>>isoniazid,
|rifampin, |pyrazinamide |and |ethambutol |for |up |to |9 |months
Know |about |description |of |IFN-β | CORRECT |ANSWER>>>(fibroblast |interferon) |IFNs |are
|biological |response |modifiers |w |an |antiviral |and |immunolodulatory |activity. |IFN-B |is |released |by
|human |cells |infected |with |certain |viruses- |help |create |resistance |to |viral |infections |by |acting |on |the
|host |tissue |cells
Type |of |pathogen |causes |malaria | CORRECT |ANSWER>>>plasmodium |parasite?
Why |systemic |chemotherapy |that |is |given |prior |to |surgery |or |radiation |is |given
| CORRECT |ANSWER>>>neoadjuvant |therapy |is |used |to |reduce |the |tumor |burden
|and |to |increase |the |effectiveness |of |the |local |txt |(126)
Tumor |lysis |syndrome |management |in |leukemia |patients | CORRECT |ANSWER>>>adequate |IV
|hydration |therapy, |& |give |allopurinol |if |hyperuricemia |is |anticipated |(129)
1
,Acrolein |is |a |toxic |metabolite |of |cyclophosphamide |and |ifosfamide |that |can |cause |what | CORRECT
|ANSWER>>>hemorrhagic |cystitis |(131)
Category |of |antineoplastic |drugs |offers |an |alternative |when |traditional |treatments |fail | CORRECT
|ANSWER>>>immunosuppressant |antineoplastic |agents |may |offer |an |alternative |(137)
2
, Topoisomerase |inhibitors |target |enzymes |that |control |changes |in |DNA | CORRECT
|ANSWER>>>by |altering |the |phosphodiester |structure |of |the |strands |during |the |normal |life |cycle |of
|the |cell
Effects |of |cholinesterase |inhibitors |have |on |the |sinoatrial |and |atrioventricular |nodes | CORRECT
|ANSWER>>>they |have |vagotonic |effects |on |the |SA |and |AV |nodes, |leading |to |bradycardia |and |AV
|block |which |may |exacerbate |syncope |or |hypotensive |events
Mechanism |of |action |of |"mixed |acting" |sympathomimetic |drugs | CORRECT |ANSWER>>>may
|directly |activate |the |release |of |NE |while |also |indirectly |causing |a |release |of |NE |(222)
Disease |that |GABA-derivative |antispasmodic |agents |used |effectively |to |control |muscle |spasm
CORRECT |ANSWER>>>multiple |sclerosis |(227)
FDA-approved |use |for |belladonna | CORRECT |ANSWER>>>for |mod-severe |pain |associated |with
|ureteral |spasm |(bladder |spasm) |that |is |not |responsive |to |non-narcotic |analgesics
Interval |for |therapeutic |effect |of |initial |warfarin |therapy | CORRECT |ANSWER>>>5-7 |days
|after |first |dose
Function |of |plasmin | CORRECT |ANSWER>>>promotes |hydrolysis |of |cross |linked |fibrin |polymers
Derivation |of |antihemorrhagic |agents | CORRECT |ANSWER>>>human |sources- |so |monitor
|for |infusion-related |reactions
Know |anticoagulant |therapy | CORRECT |ANSWER>>>p. |273
FDA-approved |drug |use |in |thrombocytopenia | CORRECT |ANSWER>>>anagrelide
Oprelvekin
Type |of |hypertensive |medication |should |preferentially |be |considered |for |African |Americans
CORRECT | ANSWER>>>calcium-channel-blockers
Drug |of |choice |for |treating |hypertension |in |pregnancy | CORRECT
ANSWER>>>methyldopa |Beta-blocker |indicated |for |hypertensive |emergencies
|
| CORRECT |ANSWER>>>labetalol |Know |renin-angiotensin-aldosterone |inhibitors
| CORRECT |ANSWER>>>Aliskiren
Therapeutic |management |of |paroxysmal |supraventricular |tachycardia | CORRECT
|ANSWER>>>flecainide
D2receptors |are |a |drug |development |target |for |which |disease? | CORRECT
|ANSWER>>>parkinson's |disease
Adverse |effects |of |chronic |phenytoin | CORRECT |ANSWER>>>behavioral |changes, |GI |symptoms,
|gingival |hyperplasia, |osteomalacia, |hirsutism, |megaloblastic |anemia
Which |drug |in |the |anxiolytic, |sedative, |and |hypnotic |category |is |a |melatonin |agonist | CORRECT
3
QUESTIONS WITH CORRECT ANSWERS
Histamine |that |is |not |found |within |mast |cells |functions | CORRECT |ANSWER>>>as |a
|neurotransmitter |in |the |brain |and |is |involved |with |neuroendocrine |control, |cardiovascular |functions,
|thermal |and |weight |regulation, |and |sleep |and |arousal |balance
what |cells |release |histamine |in |the |stomach? | CORRECT |ANSWER>>>enterochromaffin-like
|(ECL) |cells
Toxicity |of |antihistamines |has |been |reported |in |incidents |of |interactions |with: | CORRECT
|ANSWER>>>liver |enzymes
Toxic |effect |of |first-generation |antihistamines | CORRECT |ANSWER>>>convulsions, |postural
|hypotension, |and |cardiac |arrhythmias
Know |anaphylaxis | CORRECT |ANSWER>>>
Central |nervous |system |side |effect |of |antihistamines |in |the |elderly | CORRECT
|ANSWER>>>BEERs |list,
Indication |H2 |antihistamines | CORRECT |ANSWER>>>used |to |inhibit |secretion |of |gastric |cid
|with |GI |disorders
Know |initial |selection |of |antimicrobial |therapy | CORRECT |ANSWER>>>
Mechanism |of |food-drug |or |drug-drug |interactions |with |antibacterial |medications | CORRECT
ANSWER>>>
Know |multiple |drug |combination |treatment |for |tuberculosis | CORRECT |ANSWER>>>isoniazid,
|rifampin, |pyrazinamide |and |ethambutol |for |up |to |9 |months
Know |about |description |of |IFN-β | CORRECT |ANSWER>>>(fibroblast |interferon) |IFNs |are
|biological |response |modifiers |w |an |antiviral |and |immunolodulatory |activity. |IFN-B |is |released |by
|human |cells |infected |with |certain |viruses- |help |create |resistance |to |viral |infections |by |acting |on |the
|host |tissue |cells
Type |of |pathogen |causes |malaria | CORRECT |ANSWER>>>plasmodium |parasite?
Why |systemic |chemotherapy |that |is |given |prior |to |surgery |or |radiation |is |given
| CORRECT |ANSWER>>>neoadjuvant |therapy |is |used |to |reduce |the |tumor |burden
|and |to |increase |the |effectiveness |of |the |local |txt |(126)
Tumor |lysis |syndrome |management |in |leukemia |patients | CORRECT |ANSWER>>>adequate |IV
|hydration |therapy, |& |give |allopurinol |if |hyperuricemia |is |anticipated |(129)
1
,Acrolein |is |a |toxic |metabolite |of |cyclophosphamide |and |ifosfamide |that |can |cause |what | CORRECT
|ANSWER>>>hemorrhagic |cystitis |(131)
Category |of |antineoplastic |drugs |offers |an |alternative |when |traditional |treatments |fail | CORRECT
|ANSWER>>>immunosuppressant |antineoplastic |agents |may |offer |an |alternative |(137)
2
, Topoisomerase |inhibitors |target |enzymes |that |control |changes |in |DNA | CORRECT
|ANSWER>>>by |altering |the |phosphodiester |structure |of |the |strands |during |the |normal |life |cycle |of
|the |cell
Effects |of |cholinesterase |inhibitors |have |on |the |sinoatrial |and |atrioventricular |nodes | CORRECT
|ANSWER>>>they |have |vagotonic |effects |on |the |SA |and |AV |nodes, |leading |to |bradycardia |and |AV
|block |which |may |exacerbate |syncope |or |hypotensive |events
Mechanism |of |action |of |"mixed |acting" |sympathomimetic |drugs | CORRECT |ANSWER>>>may
|directly |activate |the |release |of |NE |while |also |indirectly |causing |a |release |of |NE |(222)
Disease |that |GABA-derivative |antispasmodic |agents |used |effectively |to |control |muscle |spasm
CORRECT |ANSWER>>>multiple |sclerosis |(227)
FDA-approved |use |for |belladonna | CORRECT |ANSWER>>>for |mod-severe |pain |associated |with
|ureteral |spasm |(bladder |spasm) |that |is |not |responsive |to |non-narcotic |analgesics
Interval |for |therapeutic |effect |of |initial |warfarin |therapy | CORRECT |ANSWER>>>5-7 |days
|after |first |dose
Function |of |plasmin | CORRECT |ANSWER>>>promotes |hydrolysis |of |cross |linked |fibrin |polymers
Derivation |of |antihemorrhagic |agents | CORRECT |ANSWER>>>human |sources- |so |monitor
|for |infusion-related |reactions
Know |anticoagulant |therapy | CORRECT |ANSWER>>>p. |273
FDA-approved |drug |use |in |thrombocytopenia | CORRECT |ANSWER>>>anagrelide
Oprelvekin
Type |of |hypertensive |medication |should |preferentially |be |considered |for |African |Americans
CORRECT | ANSWER>>>calcium-channel-blockers
Drug |of |choice |for |treating |hypertension |in |pregnancy | CORRECT
ANSWER>>>methyldopa |Beta-blocker |indicated |for |hypertensive |emergencies
|
| CORRECT |ANSWER>>>labetalol |Know |renin-angiotensin-aldosterone |inhibitors
| CORRECT |ANSWER>>>Aliskiren
Therapeutic |management |of |paroxysmal |supraventricular |tachycardia | CORRECT
|ANSWER>>>flecainide
D2receptors |are |a |drug |development |target |for |which |disease? | CORRECT
|ANSWER>>>parkinson's |disease
Adverse |effects |of |chronic |phenytoin | CORRECT |ANSWER>>>behavioral |changes, |GI |symptoms,
|gingival |hyperplasia, |osteomalacia, |hirsutism, |megaloblastic |anemia
Which |drug |in |the |anxiolytic, |sedative, |and |hypnotic |category |is |a |melatonin |agonist | CORRECT
3
